Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come [Seeking Alpha]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Seeking Alpha
Summary Mid-cap biotech Neurocrine Biosciences ( NBIX ) continues to rack up the good news, but the market is still reluctant to give full value to the shares. Not only will this company have two presumptive blockbusters-to-be on the market this year, but it will soon be profitable at the operating income line and it has two more potential blockbuster indications lined up relatively soon, as well as longer-dated and more speculative pipeline opportunities. Although the company continues to take what I see as a conservative approach with its pipeline, the switchover to positive free cash flow will create expanded opportunities for capital deployment for management. Another Strong Quarter Early In The Launch Cycle For Ingrezza With another quarter of revenue solidly above expectations, it is clear that Ingrezza is seeing strong demand early in its commercial launch. Prescriptions rose more than a third from the first quarter (to a little under 17,000), with revenue-per-
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesGlobeNewswire
- Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment [Yahoo! Finance]Yahoo! Finance
- Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsPR Newswire
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
NBIX
Earnings
- 2/7/24 - Beat
NBIX
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form ARS
- NBIX's page on the SEC website